Last reviewed · How we verify

NCT06212050: Neo2BAV

Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis

ENROLLING BY INVITATION Last updated 21 June 2024
What this trial tests

trial testing Transcatheter Aortic Valve Implantation in Aortic Stenosis in 200 participants. Enrolling by invitation.

Timeline
15 September 2023
Primary endpoint
1 March 2024
30 June 2024

Quick facts

Lead sponsorNational University of Ireland, Galway, Ireland
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment200
Start date15 September 2023
Primary completion1 March 2024
Estimated completion30 June 2024
Sites3 locations across Sweden, Ireland, Germany

Drugs / interventions tested

Conditions studied

Sponsor

National University of Ireland, Galway, Ireland

Who can join

18 and older, any sex, with Aortic Stenosis or Transcatheter Aortic Valve Implantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the NEO2 BAV registry is to investigate the safety, effectiveness, and clinical performance of TAVI using the ACURATE neo2 valve in patients with severe BAV stenosis. The clinical, procedural, and imaging characteristics will be collected from patients with severe BAV stenosis, regardless of the phenotype, and treated with TAVI using the ACURATE neo2 bioprosthesis worldwide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcatheter Aortic Valve Implantation

Trials testing the same drug.

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other National University of Ireland, Galway, Ireland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06212050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing